2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization …
M Glikson, JC Nielsen, MB Kronborg, Y Michowitz… - EP …, 2022 - academic.oup.com
for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …
detailed information, the user should always access to the full text version of the guidelines …
[HTML][HTML] Editor's Choice–2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular …
Document Reviewers b, Petr Widimsky, Philippe Kolh, Stefan Agewall, Héctor Bueno,
Antonio Coca, Gert J. De Borst, Victoria Delgado, Florian Dick, Cetin Erol, Marc Ferrini …
Antonio Coca, Gert J. De Borst, Victoria Delgado, Florian Dick, Cetin Erol, Marc Ferrini …
[PDF][PDF] 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
W 2011 roku ESC opublikowało pierwsze wytyczne dotyczące rozpoznawania i leczenia
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …
Calcific aortic stenosis
BR Lindman, MA Clavel, P Mathieu, B Iung… - Nature reviews Disease …, 2016 - nature.com
Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …
Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives
Transcatheter aortic valve replacement (TAVR) has become a well-accepted option for
treating patients with aortic stenosis at intermediate to high or prohibitive surgical risk. TAVR …
treating patients with aortic stenosis at intermediate to high or prohibitive surgical risk. TAVR …
5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a …
MJ Mack, MB Leon, CR Smith, DC Miller, JW Moses… - The Lancet, 2015 - thelancet.com
Summary Background The Placement of Aortic Transcatheter Valves (PARTNER) trial
showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter …
showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter …
Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis
Background: Transcatheter aortic valve replacement (TAVR) is being increasingly performed
in patients with bicuspid aortic valve stenosis (AS). Objectives: This study sought to compare …
in patients with bicuspid aortic valve stenosis (AS). Objectives: This study sought to compare …
2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or …
In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …
Transcatheter aortic valve implantation in failed bioprosthetic surgical valves
Importance Owing to a considerable shift toward bioprosthesis implantation rather than
mechanical valves, it is expected that patients will increasingly present with degenerated …
mechanical valves, it is expected that patients will increasingly present with degenerated …
Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI
V Auffret, T Lefevre, E Van Belle, H Eltchaninoff… - Journal of the American …, 2017 - jacc.org
Background: Transcatheter aortic valve replacement (TAVR) is standard therapy for patients
with severe aortic stenosis who are at high surgical risk. However, national data regarding …
with severe aortic stenosis who are at high surgical risk. However, national data regarding …